Akynzeo and Atherosclerosis - a phase IV clinical study of FDA data

Summary:

Atherosclerosis is reported only by a few people who take Akynzeo.

The phase IV clinical study analyzes which people take Akynzeo and have Atherosclerosis. It is created by eHealthMe based on reports of 915 people who have side effects while taking Akynzeo from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Aug, 17, 2022

915 people reported to have side effects when taking Akynzeo.
Among them, 4 people (0.44%) have Atherosclerosis.


What is Akynzeo?

Akynzeo has active ingredients of netupitant; palonosetron hydrochloride. eHealthMe is studying from 916 Akynzeo users for its effectiveness, alternative drugs and more.

What is Atherosclerosis?

Atherosclerosis (disorder of the arteries) is found to be associated with 2,049 drugs and 1,307 conditions by eHealthMe.

Number of Akynzeo and Atherosclerosis reports submitted per year:

Could Akynzeo cause Atherosclerosis?

Gender of people who have Atherosclerosis when taking Akynzeo *:

  • female: 100 %
  • male: 0.0 %

Age of people who have Atherosclerosis when taking Akynzeo *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 100 %

Common drugs people take besides Akynzeo *:

  1. Zestril: 4 people, 100.00%
  2. Mucomyst: 4 people, 100.00%
  3. Keytruda: 4 people, 100.00%
  4. Duphalac: 4 people, 100.00%
  5. Cyklokapron: 4 people, 100.00%
  6. Alimta: 4 people, 100.00%
  7. Acetylsalicylic Acid: 1 person, 25.00%

Common side effects people have besides Atherosclerosis *:

  1. Febrile Neutropenia (fever with reduced white blood cells): 4 people, 100.00%
  2. Pressure Ulcer: 1 person, 25.00%
  3. Peripheral Ischaemia (impaired circulation to an extremity): 1 person, 25.00%
  4. Necrosis (the death of body tissue): 1 person, 25.00%
  5. Nausea (feeling of having an urge to vomit): 1 person, 25.00%
  6. Infection: 1 person, 25.00%
  7. Fatigue (feeling of tiredness): 1 person, 25.00%
  8. Diarrhea: 1 person, 25.00%

Common conditions people have *:

  1. Type 2 Diabetes: 4 people, 100.00%
  2. Non-Small Cell Lung Cancer Metastatic (type of epithelial lung cancer spreads to other parts): 4 people, 100.00%
  3. Nausea (feeling of having an urge to vomit): 4 people, 100.00%
  4. Insomnia (sleeplessness): 4 people, 100.00%
  5. High Blood Pressure: 4 people, 100.00%
  6. High Blood Cholesterol: 4 people, 100.00%
  7. Cough: 4 people, 100.00%
  8. Constipation: 4 people, 100.00%
  9. Vitamin B12 Deficiency: 3 people, 75.00%

* Approximation only. Some reports may have incomplete information.

Do you take Akynzeo and have Atherosclerosis?

Check whether Atherosclerosis is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

How severe was Atherosclerosis and when was it recovered:

Expand to all the drugs that have ingredients of netupitant; palonosetron hydrochloride:

Alternative drugs to, pros and cons of Akynzeo:

Atherosclerosis treatments and more:

COVID vaccines that are related to Atherosclerosis:

Common drugs associated with Atherosclerosis:

All the drugs that are associated with Atherosclerosis:

Common conditions associated with Atherosclerosis:

All the conditions that are associated with Atherosclerosis:

How the study uses the data?

The study uses data from the FDA. It is based on netupitant; palonosetron hydrochloride (the active ingredients of Akynzeo) and Akynzeo (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: